CN Patent

CN100519558C — 结晶单水合物、其制备方法及其在制备药物组合中的用途

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2009-07-29 · 17y expired

What this patent protects

本发明是关于(1α，2β，4β，5α，7β)-7-[(羟基二-2-噻吩基乙酰基)氧]-9，9-二甲基-3-氧杂-9-氮鎓三环[3.3.1.0 2，4 ]壬烷溴的结晶性单水合物，其制法及其用于制/备药物组合物的用途，特别是用于制备具有抗胆碱能效果的药物组合物。

USPTO Abstract

本发明是关于(1α，2β，4β，5α，7β)-7-[(羟基二-2-噻吩基乙酰基)氧]-9，9-二甲基-3-氧杂-9-氮鎓三环[3.3.1.0 2，4 ]壬烷溴的结晶性单水合物，其制法及其用于制/备药物组合物的用途，特别是用于制备具有抗胆碱能效果的药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN100519558C
Jurisdiction
CN
Classification
—
Expires
2009-07-29
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.